Skip to main content
SpringerLink
Log in

Advances in Lymphoma Research

  • Book
  • © 1996

Overview

Editors:
  1. Fernando Cabanillas

    1. Department of Hematology, M.D. Anderson Cancer Center, Houston, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. M. Alma Rodriguez

    1. Department of Hematology, M.D. Anderson Cancer Center, Houston, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Treatment and Research (CTAR, volume 85)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (10 chapters)

  1. Front Matter

    Pages i-x
    Download chapter PDF

  2. New Therapeutic Advances

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Fludarabine phosphate in lymphoma: an important new therapeutic agent

      • Peter McLaughlin, Lester E. Robertson, Michael J. Keating
      Pages 3-14

    3. 2-Chlorodeoxyadenosine treatment of lymphoma

      • Alan Saven, Lawrence D. Piro
      Pages 15-26

  3. New Histopathologic Entities

    1. Front Matter

      Pages 27-27
      Download chapter PDF

    2. Histologic grading of nodular sclerosing Hodgkin’s disease: is it an independent prognostic factor?

      • Barbara M. Osborne, Carlos Bueso-Ramos
      Pages 29-40

    3. Mantle cell lymphomas

      • M. Alma Rodriguez, William C. Pugh
      Pages 41-50

  4. New Perspectives on Clinical Prognostic Parameters and Treatment

    1. Front Matter

      Pages 51-51
      Download chapter PDF

    2. Can prognostic factors be applied in treatment selection for aggressive lymphoma patients?

      • Bertrand Coiffier
      Pages 53-77

    3. Factors that influence prognosis of intermediate-grade lymphomas at relapse

      • M. Alma Rodriguez
      Pages 79-86

    4. High-dose chemotherapy in non-Hodgkin’s lymphoma

      • Jean-Yves Blay, Thierry O. Philip
      Pages 87-103

  5. New Biomolecular Markers/Targets

    1. Front Matter

      Pages 105-105
      Download chapter PDF

    2. The phenomenon of multidrug resistance in non-Hodgkin’s lymphoma

      • Thomas P. Miller, Ellen M. Chase, William S. Dalton, Thomas M. Grogan
      Pages 107-117

    3. Adhesion molecules in non-Hodgkin’s lymphoma

      • Philip T. Neff, Bradley W. McIntyre
      Pages 119-139

    4. PCR monitoring of response in patients treated with high-dose chemotherapy for low-grade lymphoma

      • John G. Gribben
      Pages 141-160

  6. Back Matter

    Pages 161-169
    Download chapter PDF
Back to top

Keywords

About this book

Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third­ generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results.

Editors and Affiliations

  • Department of Hematology, M.D. Anderson Cancer Center, Houston, USA

    Fernando Cabanillas, M. Alma Rodriguez

Bibliographic Information

  • Book Title: Advances in Lymphoma Research

  • Editors: Fernando Cabanillas, M. Alma Rodriguez

  • Series Title: Cancer Treatment and Research

  • DOI: https://doi.org/10.1007/978-1-4615-4129-5

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 1996

  • Hardcover ISBN: 978-0-7923-3929-8Published: 28 February 1997

  • Softcover ISBN: 978-1-4613-6851-9Published: 08 October 2012

  • eBook ISBN: 978-1-4615-4129-5Published: 06 December 2012

  • Series ISSN: 0927-3042

  • Series E-ISSN: 2509-8497

  • Edition Number: 1

  • Number of Pages: XI, 169

  • Topics: Oncology, Cancer Research

Publish with us

Policies and ethics

Back to top

Search

Navigation